Main Menu

This technology involves the discovery and characterization of a novel cell surface antigen uniquely expressed on activated T regulatory (Treg) cells, serving as a receptor for latent transforming growth factor beta-1 (TGF-β1). To explore its role in immune regulation, a specific monoclonal antibody was developed through immunization of hamsters, capable of recognizing this antigen with high specificity.

The technology revolves around the discovery of SIRPα (Signal Regulatory Protein alpha) expression on CD8+ T cells as a novel biomarker for assessing T cell functionality during immune exhaustion, a state commonly induced by chronic infections and cancer. The unique expression profile of SIRPα on a subset of functional CD8+ T cells that retain cytotoxic capabilities despite an exhausted phenotype opens new avenues for therapeutic interventions.

The technology revolves around an innovative monoclonal antibody-based conditioning regimen for enhancing the engraftment of hematopoietic stem cells during bone marrow transplants. It features a novel antibody-drug conjugate that targets CD117, a marker on stem cells, to enable effective transplantation without the harmful side effects of traditional conditioning methods.

The technology pertains to a novel polymer nanoparticle platform designed for the creation of individualized cancer vaccines. It utilizes a two-component system that combines patient-specific peptide neoantigens with immunostimulants within self-assembling nanoparticles. This approach ensures the targeted delivery of neoantigens to the immune system, enhancing the immune response against cancer cells while avoiding the systemic activation often seen with conventional adjuvants.

This technology presents a novel strain of transgenic mice where the proto-oncogene c-Cbl (Casitas B-lineage lymphoma) has been engineered with loxP (locus of X-over P1) sites, commonly referred to as "floxed." This design enables the conditional knockout of the c-Cbl gene when the mice are crossed with strains that express the Cre recombinase enzyme. Cre recombinase is an enzyme that can specifically target loxP sites, excising the floxed gene only in the presence of Cre, thus allowing tissue-specific or temporal deletion of the target gene.

This innovative technology centers on advanced peptide-based vaccine formulations that aim to significantly boost T cell-mediated immune responses. The core of this invention is the strategic conjugation of modified peptides with polymers attached to immunostimulants, a design poised to enhance the efficacy of vaccines. This approach not only promises to refine the manufacturing process, making it more efficient but also aims to augment the generation of immune responses, potentially leading to superior vaccine performance against various pathogens.

The technology pertains to the development of furin-deficient Chinese Hamster Ovary (CHO) cells, specifically the CHO FD11 cell line, which plays a pivotal role in proteolytic maturation of various proteins critical for physiological processes and pathogen virulence. By inhibiting furin, a protease involved in the activation of many important proteins and pathogens, these modified cells provide a unique platform for research into viral infections and potential therapeutic interventions.

The discovery of RPS3 and phospho-RPS3 antibodies represents a significant advancement in understanding mammalian gene regulation and its implications for disease. These antibodies serve as critical tools for detecting and studying the NF-kB transcription factor, particularly its specifier subunit RPS3 and its phosphorylated form. By enabling the precise identification and localization of these regulatory proteins, this technology opens avenues for investigating their roles in various diseases, including cancer and immune disorders.

This technology includes a Dengue-2 isolated virus for use as a cancer vaccine therapeutic.

This technology includes Klebsiella pneumoniae isolate to be used for research studies and diagnostic tests to detect antimicrobial resistance.